{"transactions":[{"id":3585618,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-08T22:08:51.000Z","date":"2026-09-08","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options granted under the Issuer's 2012 Equity Incentive Plan (the \"Plan\"). The option is fully vested."}],"balance_after":274430,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001628280-26-060962","document":"wk-form4_1788905328.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026060962/wk-form4_1788905328.xml","form_type":"4"}},{"id":3585617,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-09-08T22:08:51.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":16.4566,"value":41141.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.29 to $16.59, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":17217,"source":{"system":"sec-edgar","filing":"0001628280-26-060962","document":"wk-form4_1788905328.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026060962/wk-form4_1788905328.xml","form_type":"4"}},{"id":3585616,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-09-08T22:08:51.000Z","date":"2026-09-08","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":1.01,"value":2525.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":19717,"source":{"system":"sec-edgar","filing":"0001628280-26-060962","document":"wk-form4_1788905328.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026060962/wk-form4_1788905328.xml","form_type":"4"}},{"id":698968,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-03T22:14:32.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options granted under the Issuer's 2012 Equity Incentive Plan (the \"Plan\"). The option is fully vested."}],"balance_after":276930,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001628280-26-052031","document":"wk-form4_1785795270.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026052031/wk-form4_1785795270.xml","form_type":"4"}},{"id":698967,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-08-03T22:14:32.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":16.0116,"value":40029.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.06, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":17217,"source":{"system":"sec-edgar","filing":"0001628280-26-052031","document":"wk-form4_1785795270.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026052031/wk-form4_1785795270.xml","form_type":"4"}},{"id":698966,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-08-03T22:14:32.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":1.01,"value":2525.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":19717,"source":{"system":"sec-edgar","filing":"0001628280-26-052031","document":"wk-form4_1785795270.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026052031/wk-form4_1785795270.xml","form_type":"4"}},{"id":712734,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-08T22:49:19.000Z","date":"2026-07-08","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options granted under the Issuer's 2012 Equity Incentive Plan (the \"Plan\"). The option is fully vested."}],"balance_after":279430,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001628280-26-047710","document":"wk-form4_1783550956.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026047710/wk-form4_1783550956.xml","form_type":"4"}},{"id":712733,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-07-08T22:49:19.000Z","date":"2026-07-08","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":16,"value":40000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":17217,"source":{"system":"sec-edgar","filing":"0001628280-26-047710","document":"wk-form4_1783550956.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026047710/wk-form4_1783550956.xml","form_type":"4"}},{"id":712732,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-07-08T22:49:19.000Z","date":"2026-07-08","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":1.01,"value":2525.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":19717,"source":{"system":"sec-edgar","filing":"0001628280-26-047710","document":"wk-form4_1783550956.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026047710/wk-form4_1783550956.xml","form_type":"4"}},{"id":721385,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-01T23:04:05.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options granted under the Issuer's 2012 Equity Incentive Plan (the \"Plan\"). The option is fully vested."}],"balance_after":118417,"derivative":{"exercise_price":1.26,"expiration_date":"2028-11-13","underlying":"Class A Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001628280-26-046653","document":"wk-form4_1782947042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026046653/wk-form4_1782947042.xml","form_type":"4"}},{"id":721384,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-01T23:04:05.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options granted under the Issuer's 2012 Equity Incentive Plan (the \"Plan\"). The option is fully vested."}],"balance_after":281930,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001628280-26-046653","document":"wk-form4_1782947042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026046653/wk-form4_1782947042.xml","form_type":"4"}},{"id":721383,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-07-01T23:04:05.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":16.008,"value":160080.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.12, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,605 shares of the Issuer's Class A Common Stock acquired by the Reporting Person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c)."}],"balance_after":17217,"source":{"system":"sec-edgar","filing":"0001628280-26-046653","document":"wk-form4_1782947042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026046653/wk-form4_1782947042.xml","form_type":"4"}},{"id":721382,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-07-01T23:04:05.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":1.26,"value":3150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":27217,"source":{"system":"sec-edgar","filing":"0001628280-26-046653","document":"wk-form4_1782947042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026046653/wk-form4_1782947042.xml","form_type":"4"}},{"id":721381,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-07-01T23:04:05.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":1.01,"value":7575.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":24717,"source":{"system":"sec-edgar","filing":"0001628280-26-046653","document":"wk-form4_1782947042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000162828026046653/wk-form4_1782947042.xml","form_type":"4"}},{"id":740129,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T20:16:21.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027."}],"balance_after":25000,"derivative":{"exercise_price":2.63,"exercise_date":"2027-06-10","expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001861519-26-000002","document":"wk-form4_1781295377.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000186151926000002/wk-form4_1781295377.xml","form_type":"4"}},{"id":879853,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-26T21:40:40.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":false,"shares":2700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options are fully vested and exercisable."}],"balance_after":120917,"derivative":{"exercise_price":1.26,"expiration_date":"2028-11-13","underlying":"Class A Common Stock","underlying_shares":2700},"source":{"system":"sec-edgar","filing":"0001437749-26-005892","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926005892/rdgdoc.xml","form_type":"4"}},{"id":879852,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-26T21:40:40.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":false,"shares":4400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options are fully vested and exercisable."}],"balance_after":123617,"derivative":{"exercise_price":1.26,"expiration_date":"2028-11-13","underlying":"Class A Common Stock","underlying_shares":4400},"source":{"system":"sec-edgar","filing":"0001437749-26-005892","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926005892/rdgdoc.xml","form_type":"4"}},{"id":879851,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-02-26T21:40:40.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":2700,"price":16.0155,"value":43241.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.05, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":14954,"source":{"system":"sec-edgar","filing":"0001437749-26-005892","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926005892/rdgdoc.xml","form_type":"4"}},{"id":879850,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-02-26T21:40:40.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":true,"shares":2700,"price":1.26,"value":3402.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":17654,"source":{"system":"sec-edgar","filing":"0001437749-26-005892","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926005892/rdgdoc.xml","form_type":"4"}},{"id":879849,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-02-26T21:40:40.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":4400,"price":16.0195,"value":70485.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":14954,"source":{"system":"sec-edgar","filing":"0001437749-26-005892","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926005892/rdgdoc.xml","form_type":"4"}},{"id":879848,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-02-26T21:40:40.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":true,"shares":4400,"price":1.26,"value":5544.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":19354,"source":{"system":"sec-edgar","filing":"0001437749-26-005892","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926005892/rdgdoc.xml","form_type":"4"}},{"id":905369,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-13T21:27:47.000Z","date":"2026-02-11","kind":"exercise","planned":true,"acquired":false,"shares":400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options are fully vested and exercisable."}],"balance_after":128017,"derivative":{"exercise_price":1.26,"expiration_date":"2028-11-13","underlying":"Class A Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001437749-26-004126","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926004126/rdgdoc.xml","form_type":"4"}},{"id":905368,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-02-13T21:27:47.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":400,"price":16,"value":6400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":14954,"source":{"system":"sec-edgar","filing":"0001437749-26-004126","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926004126/rdgdoc.xml","form_type":"4"}},{"id":905367,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Class A Common Stock","published_at":"2026-02-13T21:27:47.000Z","date":"2026-02-11","kind":"exercise","planned":true,"acquired":true,"shares":400,"price":1.26,"value":504.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,246 shares purchased through Issuer's Employee Stock Purchase Plan on November 15, 2024 and 2,096 shares purchased through Issuer's Employee Stock Purchase Plan on May 15, 2025."}],"balance_after":15354,"source":{"system":"sec-edgar","filing":"0001437749-26-004126","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926004126/rdgdoc.xml","form_type":"4"}},{"id":927108,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-30T21:56:17.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":445000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service."}],"balance_after":445000,"derivative":{"exercise_price":14.26,"expiration_date":"2036-01-29","underlying":"Class A Common Stock","underlying_shares":445000},"source":{"system":"sec-edgar","filing":"0001437749-26-002577","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774926002577/rdgdoc.xml","form_type":"4"}},{"id":1183788,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-03T00:11:50.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on April 1, 2026."}],"balance_after":20000,"derivative":{"exercise_price":2.93,"exercise_date":"2026-04-01","expiration_date":"2035-04-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001372514-25-000026","document":"wk-form4_1743639103.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000137251425000026/wk-form4_1743639103.xml","form_type":"4"}},{"id":1289686,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-31T21:35:27.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service."}],"balance_after":300000,"derivative":{"exercise_price":9.79,"expiration_date":"2035-01-30","underlying":"Class A Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001437749-25-002424","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774925002424/rdgdoc.xml","form_type":"4"}},{"id":1408761,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-12T10:32:55.000Z","date":"2024-09-11","kind":"purchase","planned":false,"acquired":true,"shares":1250,"price":3.68,"value":4600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $3.65 to $3.73. The reported price of $3.68 represents the volume weighted average price for the reported transaction. The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":1250,"source":{"system":"sec-edgar","filing":"0001372514-24-000115","document":"wk-form4_1726137169.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000137251424000115/wk-form4_1726137169.xml","form_type":"4"}},{"id":1460333,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-03T19:16:09.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":1778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on July 1, 2025."}],"balance_after":1778,"derivative":{"exercise_price":4.35,"exercise_date":"2025-07-01","expiration_date":"2034-07-01","underlying":"Common Stock","underlying_shares":1778},"source":{"system":"sec-edgar","filing":"0001372514-24-000093","document":"wk-form4_1720034163.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000137251424000093/wk-form4_1720034163.xml","form_type":"4"}},{"id":1499298,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":true,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-29T21:59:53.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":285000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on April 5, 2025, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service."}],"balance_after":285000,"derivative":{"exercise_price":15.76,"expiration_date":"2034-05-23","underlying":"Class A Common Stock","underlying_shares":285000},"source":{"system":"sec-edgar","filing":"0001437749-24-018626","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000143774924018626/rdgdoc.xml","form_type":"4"}},{"id":1767841,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":27207,"kind":"person","name":"Stengone Carmine N.","position":1,"cik":"0001861519","reported_name":"Stengone Carmine N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-10-03T20:45:28.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on September 29, 2024."}],"balance_after":8000,"derivative":{"exercise_price":0.5677,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001372514-23-000145","document":"wk-form4_1696365916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861519/000137251423000145/wk-form4_1696365916.xml","form_type":"4"}}]}